Chase Investment Counsel’s West Pharmaceutical WST Stock Holding History

Chase Investment Counsel’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$219K	Hold	874	–	–	0.06%	141
2025 Q4	$240K	Hold	874	–	–	0.07%	123
2025 Q3	$229K	Buy	+874	New	+$212K	0.07%	123
2025 Q1	–	Sell	-1,009	Closed	-$330K	–	154
2024 Q4	$330K	Hold	1,009	–	–	0.11%	118
2024 Q3	$302K	Hold	1,009	–	–	0.1%	115
2024 Q2	$332K	Sell	1,009 -31	-3%	-$11K	0.12%	112
2024 Q1	$411K	Hold	1,040	–	–	0.15%	104
2023 Q4	$366K	Buy	+1,040	New	+$368K	0.16%	107
2017 Q1	–	Sell	-5,980	Closed	-$507K	–	104
2016 Q4	$507K	Sell	5,980 -2,355	-28%	-$185K	0.25%	73
2016 Q3	$620K	Sell	8,335 -500	-6%	-$39.7K	0.27%	70
2016 Q2	$670K	Sell	8,835 -485	-5%	-$35.3K	0.3%	70
2016 Q1	$646K	Buy	+9,320	New	+$561K	0.28%	66
2014 Q1	–	Sell	-35,270	Closed	-$1.73M	–	117
2013 Q4	$1.73M	Sell	35,270 -19,290	-35%	-$903K	0.51%	64
2013 Q3	$2.25M	Buy	54,560 +60	+0.1%	+$2.29K	0.58%	40
2013 Q2	$1.91M	Buy	+54,500	New	+$1.79M	0.51%	45

Other funds holding WST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Chase Investment Counsel's WST Position: Q1 2026 in Review

Chase Investment Counsel held its West Pharmaceutical (WST) position steady in Q1 2026 at 874 shares worth $219K. The position accounts for 0.06% of the portfolio, ranked #141.

Chase Investment Counsel first reported a position in WST in Q2 2013 and has held it in 15 quarters since. The position peaked at $2.25M in Q3 2013. 753 funds tracked by Wall St. Rank hold WST as of Q1 2026.

Chase Investment Counsel held 874 shares of West Pharmaceutical worth $219K as of Q1 2026.
Chase Investment Counsel left its West Pharmaceutical share count unchanged in Q1 2026.
West Pharmaceutical made up 0.06% of Chase Investment Counsel's portfolio in Q1 2026, its #141 holding.
Chase Investment Counsel first reported a position in West Pharmaceutical in Q2 2013 and has held it in 15 quarters since.
Chase Investment Counsel's West Pharmaceutical position peaked at $2.25M in Q3 2013.
753 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Chase Investment Counsel's 13F filing for Q1 2026, filed 12 May 2026.